Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Baughman

Pulmonary Disease Cincinnati, OH Medical Doctor

NPI 1417912783 CMS profile 517646

222 Piedmont Ave, Cincinnati, OH 45219

Open in the dashboard

General payments

$639,821

367 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$463,478 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Robert Baughman of Cincinnati, OH is reported in the CMS Open Payments database as having received $639,821 across 367 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $463,478 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,908 13
2024 General $94,026 41
2023 General $113,659 51
2022 General $162,765 85
2021 General $127,283 96
2020 General $42,900 33
2019 General $65,280 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Baughman
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robert Baughman were reported at $33,908. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robert Baughman Pulmonary Disease median Middle half National median
2019 $65,280 $377 $109–$1,340 $163
2020 $42,900 $230 $56–$907 $114
2021 $127,283 $269 $68–$1,072 $132
2022 $162,765 $390 $100–$1,457 $149
2023 $113,659 $419 $114–$1,659 $160
2024 $94,026 $476 $123–$1,818 $164
2025 $33,908 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mallinckrodt Hospital Products Inc. $518,503 278 payments
  2. Mallinckrodt Enterprises LLC $56,392 40 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $30,432 19 payments
  4. United Therapeutics Corporation $18,272 17 payments
  5. Actelion Pharmaceuticals, Ltd $8,700 3 payments
  6. AbbVie, Inc. $4,513 3 payments
  7. CSL Behring $2,771 1 payment
  8. Actelion Pharmaceuticals US, Inc. $103 1 payment
  9. Janssen Research & Development, LLC $67 3 payments
  10. Merck Sharp & Dohme Corporation $51 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $548,600 122 payments
  2. Travel and Lodging $54,786 93 payments
  3. Consulting Fee $28,054 9 payments
  4. Food and Beverage $8,338 141 payments
  5. Gift $41 1 payment
  6. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. ACTHAR Immunology $518,503 278 payments
  2. ACTHAR Autoimmune And Rare Disease $56,392 40 payments
  3. OFEV $20,168 10 payments
  4. Zemaira $2,771 1 payment
  5. TYVASO $1,531 6 payments
  6. UPTRAVI $67 3 payments
  7. WINREVAIR $51 1 payment
  8. Adempas $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record